Gavinaaf 

Presentation: Gavinaaf Oral Suspension, available in Bangladesh, is presented as a liquid suspension, typically in a 200 ml bottle. The formulation contains Sodium Alginate 500 mg, Sodium Bicarbonate 267 mg, and Calcium Carbonate 160 mg per 10 ml.

Indications: Gavinaaf is indicated for the symptomatic relief of:

• Gastric reflux  
• Heartburn  
• Indigestion  
• Flatulence associated with gastric reflux  
• Heartburn of pregnancy  
• All cases of epigastric and retrosternal distresswhere the underlying cause is gastric reflux.  

Dosage and Administration: Gavinaaf is for oral administration and should be taken after meals and at bedtime, up to four times a day.

• Adults and children over 12 years: 10-20 ml.
• Children 6 to 12 years: 5-10 ml.
• Children under 6 years: Not recommended.
• Elderly: No dose modifications necessary.

A time interval of 2 hours should be considered between the intake of Gavinaaf and other medicinal products, especially tetracyclines, digoxin, fluoroquinolones, iron salts, ketoconazole, neuroleptics, thyroid hormones, penicillamine, beta-blockers (atenolol, metoprolol, propanolol),and glucocorticoids.

Side Effects: In addition to the desired effect, some side effects may appear, such as:

• Constipation
• Flatulence
• Stomach cramps
• Belching

In case of a large overdose, a sensation of swelling may occur.

Precautions: Gavinaaf is contraindicated in patients with known or suspected hypersensitivity to the active ingredients or any of the excipients.

Caution should be taken in patients with:

• A highly restricted salt diet (each 10 ml dose contains 141 mg of sodium).
• Hypercalcaemia, nephrocalcinosis, and recurrent calcium-containing renal calculi (each 10 ml dose contains 160 mg of calcium carbonate).
• Phenylketonuria (due to aspartame content in some formulations).

If symptoms do not improve after seven days, the clinical situation should be reviewed.

Use in Pregnancy and Breastfeeding: Clinical studies in pregnant women and post-marketing experience indicate no malformative nor feto/neonatal toxicity of the active ingredients. Gavinaaf can be used during pregnancy and breastfeeding if clinically needed.

Storage: Store in a cool (below 30°C) and dry place, away from light. Keep out of reach of children. Do not refrigerate or freeze.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.